Researcher Database

Suzuki Risako

■Faculty	Medical Oncology
■Position	Assistant Professor

Last Updated :2026/05/29

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), May 2024, Peer-reviewed

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment., Hirasawa Yuya;Kubota Yutaro;Mura Emiko;Suzuki Risako;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Ohkuma Ryotaro;Shimokawa Masahiro;Ariizumi Hirotsugu;Horiike Atsushi;Wada Satoshi;Ariyoshi Tomotake;Goto Satoru;Otsuka Koji;Murakami Masahiko;Kiuchi Yuji;Yoshimura Kiyoshi;Hoffman Robert M;Tsunoda Takuya, Anticancer research, 44(8):3397 - 3407, 2024, Peer-reviewed

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S., Front Immunol, 14:1260492, Sep. 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1260492

Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary., Suzuki Risako;Hamada Kazuyuki;Ohkuma Ryotaro;Homma Mayumi;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Kubota Yutaro;Horiike Atsushi;Yoshimura Kiyoshi;Wada Satoshi;Yamochi Toshiko;Tsunoda Takuya, Frontiers in oncology, 13, Jul. 2023

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, May 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1164724